0
0
0
0
1
2
3
$0
Is Bristol Myers Squibb solid or fragile? The Finex Financial Health Scanner reads BMY's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $48.2B |
|---|---|
| Net income | $7.1B |
| Operating margin | 20.8% |
| Net margin | 14.6% |
| Cash and investments | $10.7B |
| Total debt | $45.1B |
| Free cash flow | $6.4B |
| Revenue growth (1 year) | -0.2% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.